The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy
Open accessAbstract
This large community-based cohort study investigates the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Liraglutide and Semaglutide, on the risk of developing psychiatric conditions such as depression, anxiety, and suicidal behaviors in patients with obesity. Utilizing post-marketing data, this research compares patients prescribed GLP-1 RAs (cases) with those not taking these medications (controls). The analysis spanned data from January 1, 2015, to December 31, 2023. To minimize selection bias, we employed 1:1 propensity score matching to account for demographic factors such as age, sex, race, and comorbidities. After matching, the study included 162,253 case and control patients. This study showed a significant association between GLP-1 RA treatment and an 98% increased risk of any psychiatric disorders. Notably, patients on GLP-1 RAs exhibited a 195% higher risk of major depression, a 108% increased risk for anxiety, and a 106% elevated risk for suicidal behavior. These findings underscore the critical need for physicians to thoroughly assess patient history before prescribing GLP-1 RAs and highlight the urgent requirement for further prospective clinical trials to fully understand the implications of GLP-1 RA use on mental health in the obese patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Suicidal ideation is associated with the use of various weight reduction drugs [67,68].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Kornelius et al. reported a three-fold higher risk of major depression, and a doubled risk for anxiety and suicidal behavior in a large (n = 11,683,623) retrospective study of GLP-1RA users utilizing the TrinetX database (100).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Childhood obesity: public-health crisis, common sense cure
Ebbeling, C. B., Pawlak, D. B., & Ludwig, D. S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09678-2 · Cited by 2,980
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Body-mass index and mortality among 1.46 million white adults
Berrington de Gonzalez, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., MacInnis, R. J., Moore, S. C., Tobias, G. S., Anton-Culver, H., Freeman, L. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000367 · Cited by 2,317
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Benefits and Risks of Bariatric Surgery in Adults: A Review
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020) · JAMA · doi:10.1001/jama.2020.12567 · Cited by 1,251
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–142 of 142
Suicidality signals in metabolic drugs: A thirty-year echo of concern
Kukreja, S., & Sagar, R. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.104943
Tronieri, J. S., Kushner, R. F., Apovian, C. M., Fitch, A., Still, C. D., & Wadden, T. A. (2026) · Obesity · doi:10.1002/oby.70183
Тимербулатов, И. Ф., Evdokimova, T. E., Tetenova, E. J., & Надеждин, А. В. (2026) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2603-01
Lieu, C. V., Zhang, C., Loganathan, N., French, L., Krunic, A., Cash, S. B., Shi, J., Lee, J., Prentice, K. J., Cummins, C. L., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102366
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 1
Weiss, A., & Ding, Y. (2026) · Brain Circulation · doi:10.4103/bc.bc_210_25
Glucagon-like Peptide-1 Receptor Agonists in Mental Health – Cognitive and Psychiatric Outcomes
Desai, D., Kulkarni, S., Gadhvi, J., Saha, S., Chaudhury, S., & Patel, M. K. (2026) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_279_25
Chen, X.-R., Mao, X.-P., Luo, D., Chang-qing, Y., & Bai, J.-N. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1799254
Kenkishvili, A. S., Panova, G. S., Kondratenko, A. R., & Maksimov, M. L. (2026) · doi:10.33920/med-13-2602-04
Depression Associated with Other Medical Conditions
Sunzeri, F., & Sunzeri, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_12
GLP-1 drugs like Ozempic show promise for more than weight loss. But what’s science vs hype?
Joyce, P. (2026) · The Conversation · doi:10.64628/aa.y3rgpa3qr
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
Xu, W., Lu, C., Xu, J., & Wang, L. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106846
Malbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004
Mills, A. M., & Noble, E. E. (2026) · Appetite · doi:10.1016/j.appet.2026.108729
Distributed Semiparametric Inference for Heterogeneous Sites via Single-Round Communication
Wang, J., Wang, Y., Ye, Z., & Chen, Y. (2026) · Journal of the American Statistical Association · doi:10.1080/01621459.2026.2709669
Liang, J., Bo, L., Miao, X., Guo, X., Xu, J., He, J., & Ye, X. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01190-4
Batra, K., Khubchandani, J., Batra, R., & Ali, S. A. (2026) · Diabetology · doi:10.3390/diabetology7080144
Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care
Haidar, L., Ruderman, S. A., Leong, C., Doupe, M. B., Lesko, C. R., Delaney, J. A., Alba, D. L., Drumright, L. N., Fojo, A. T., Fredericksen, R. J., et al. (2026) · AIDS · doi:10.1097/qad.0000000000004598
Tseng, K.-Y., Kuo, T., Chang, P.-K., Chou, J.-L., Huang, E. Y., Greig, N. H., Choi, H.-I., Olson, L., Hoffer, B. J., & Chen, Y.-H. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261477621
Buczkowska, A., Glinski, M., Danieluk, J., Adamaszek, N., Kacprzak, U., Dołęga-Mostowska, D., Stochaj, L., Flejszman, M., Wójcik, J., & Sochowska, J. (2026) · Cureus · doi:10.7759/cureus.114435
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Porwolik, A., Porwolik, H., Cyran, P., Szydłowski, R., Bodera, M., & Skotarski, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5185
GLP-1 receptor agonists in diabetes-associated neurological disorders
Rasooli, R., Sharifzadeh, M., Rassouli, A., & Bekheir, S. A. (2026) · Brain Disorders · doi:10.1016/j.dscb.2026.100326
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
Lubo, C., Bustamante, R., Quintana-Espinosa, L., & Guillen-Burgos, H. F. (2026) · Brain Sciences · doi:10.3390/brainsci16090926
Nascimento, G. L. M., da Silva, B. W. V., de Souza, F. V., Corrêa, S. B. P., Machado, V. D. F., SILVA, I. R. D., Lopatiuk, C. E., SILVA, T. O. D., Andrade, A. N. D., & Castro, M. A. D. A. (2026) · Aracê. · doi:10.56238/arev8n8-136
Quadir, A., Devi, R., Allah, B. J., Haider, A., Shaikh, S. S., & Botsa, K. N. (2026) · Cureus · doi:10.7759/cureus.115703
Adipocyte-specific MC2R overexpression exerts minimal metabolic effects in mice
Lim, S., Evallo, E., Kim, D., & Park, M.-J. (2026) · Laboratory Animal Research · doi:10.1186/s42826-026-00296-4
Ndiulor, M., Wang, H., Neba, R. A., Rasu, R. S., Zhou, B., & Sambamoorthi, U. (2026) · Healthcare · doi:10.3390/healthcare14182971
Barreto, L. L., Fernandes, A. M., Rocha, J. F., dos Santos, I. M. V. E. S. R., Aires, G. B., Rocha, G. Z. D. S., & Cardoso, R. A. (2026) · Revista Master Ensino Pesquisa e Extensão · doi:10.47224/revistamaster.v11i21.857
Bukowska, M., Otrębska, K., Lewandowska, D., & Jastrzębska, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6563
Erkan, İ. B. Ö., Senturk, L. M., Erel, C. T., Seyisoğlu, H., Şahmay, S., & Durmuşoğlu, F. (2026) · Climacteric · doi:10.1080/13697137.2026.2735765
Sanborn, J., Robertson, M., Nash, D., Fleary, S. A., Piltch-Loeb, R., Shen, Y., Nuñez, J., Balasubramanian, S., & Parcesepe, A. M. (2026) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2026.101193
Zoller, A. R., Athinarayanan, S., Bernstein, M., Adams, R., & Cardel, M. (2026) · Research Square · doi:10.21203/rs.3.rs-10695294/v1
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies
Kounatidis, D. C., Vallianou, N. G., Kouveletsou, M., Kontrafouri, P., Stamatopoulos, V., Rebelos, E., Diakoumopoulou, E., & Dalamaga, Μ. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00770-z
Gędek, A., Modrzejewski, S., Polański, K., Waśniewska, L., Molero, P., Wichniak, A., Dominiak, M., & McIntyre, R. S. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.113886
Palmisano, M., Mrizak, H., Gonzalez, A. E., Onge, C. M. S., Erikson, C. M., Cruz, B., Flores‐Bonilla, A., Vlkolinský, R., Sharlai, O., Benedict, J., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111240
Vashisht, R., Dhruva, S. S., Patel, A., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Koliwad, S. K., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261498914
McNeel, K., Bhanji, Z., Le, V., Lee, J., & Gallicano, I. (2026) · Considerations in Medicine · doi:10.1136/conmed-2026-000096
Miya, A., Kaneko, M., Ozaki, Y., Kameda, H., & Nakamura, A. (2026) · Diabetology International · doi:10.1007/s13340-026-00942-1
Metadata
- Authors
- Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S.
- Affiliations
- Chung Shan Medical University Hospital (TW)
- Corresponding author
- Yang, Yi-Sun
- Venue
- Scientific Reports
- Published
- 2024-10-18
- Volume
- 14
- Issue
- 1
- Pages
- 24433-24433
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC11489776
- OpenAlex
- W4403514301
- Cited by
- 143
- References
- 46
- Citations by year
- 2026: 70 · 2025: 68 · 2024: 4
- FWCI
- 46.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Chung Shan Medical University Hospital (CSH-2020-C-016)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- GLP-1 receptor agonists, obesity, depression, anxiety, suicidal behavior, psychiatric adverse effects, liraglutide, semaglutide, mental health, drug safety
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Anxiety, Depression, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Risk Factors, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
